Maze Therapeutics, Inc. (NASDAQ:MAZE) Stock Rated “Buy” by Sell-Side Brokerages

Maze Therapeutics, Inc. (NASDAQ:MAZE) has earned an average rating of “Buy” from the fourteen ratings firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, ten have issued a buy rating and three have issued a strong buy rating on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $64.45.

Several brokerages recently commented on MAZE. Wedbush reaffirmed an “outperform” rating and set a $48.00 target price on shares of Maze Therapeutics in a report on Wednesday, September 23rd. BTIG Research reissued a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a report on Tuesday, September 22nd. Citigroup started coverage on shares of Maze Therapeutics in a research report on Wednesday, September 23rd. They set a “buy” rating and a $50.00 price objective for the company. TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $110.00 target price on shares of Maze Therapeutics in a research report on Thursday, September 24th.

Maze Therapeutics Stock Performance

MAZE opened at $31.48 on Monday. The business’s 50-day simple moving average is $27.49 and its 200 day simple moving average is $31.99. Maze Therapeutics has a 52-week low of $21.95 and a 52-week high of $53.65. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. The firm has a market capitalization of $1.75 billion, a PE ratio of -12.49 and a beta of 2.16.

Maze Therapeutics (NASDAQ:MAZE) last issued its earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, hitting the consensus estimate of ($0.76). As a group, sell-side analysts expect that Maze Therapeutics will post -2.70 earnings per share for the current fiscal year.

Insider Buying and Selling at Maze Therapeutics

In other Maze Therapeutics news, insider Courtney Phillips sold 2,012 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total value of $52,332.12. Following the transaction, the insider directly owned 7,007 shares of the company’s stock, valued at $182,252.07. This trade represents a 22.31% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Jason V. Coloma sold 34,501 shares of the company’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $27.02, for a total value of $932,217.02. Following the sale, the chief executive officer owned 15,558 shares of the company’s stock, valued at $420,377.16. The trade was a 68.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 192,991 shares of company stock worth $5,187,559. 5.30% of the stock is currently owned by company insiders.

Institutional Trading of Maze Therapeutics

A number of hedge funds have recently made changes to their positions in MAZE. ARCH Venture Management LLC bought a new position in shares of Maze Therapeutics during the 2nd quarter worth approximately $122,983,582. Alphabet Inc. purchased a new position in shares of Maze Therapeutics during the second quarter valued at approximately $41,435,000. TRV GP IV LLC bought a new position in shares of Maze Therapeutics during the second quarter valued at about $133,502,907. Frazier Life Sciences Management L.P. grew its holdings in shares of Maze Therapeutics by 10.2% in the second quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock valued at $150,182,000 after acquiring an additional 465,641 shares in the last quarter. Finally, Jupiter Topco LLC bought a new position in Maze Therapeutics during the second quarter valued at about $101,764,000.

About Maze Therapeutics

Maze Therapeutics, Inc is a biopharmaceutical company focused on developing precision medicines for patients with genetically driven diseases. The company uses human genetics and its proprietary Maze Compass platform to identify disease mechanisms, discover drug targets and design therapies intended to address the underlying biology of serious conditions.

Maze’s pipeline has included small-molecule programs for rare diseases, including MZE001, an investigational glycogen synthase 1 inhibitor being developed for Pompe disease.